AbCellera Expands Multi|Target Antibody Discovery Collaboration ...

AbCellera Expands Multi-Target Antibody Discovery Collaboration ...

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (Nasdaq: REGN) to ...

AbCellera Expands Multi-Target Antibody Discovery Collaboration ...

AbCellera announced today that it has expanded its existing multi-target collaboration with Regeneron to discover therapeutic antibodies for up to eight ...

AbCellera and Lilly Expand Collaboration to Develop Antibody ...

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover ...

AbCellera, Regeneron expand antibody discovery collaboration

AbCellera and Regeneron have extended their current multi-target collaboration to discover therapeutic antibodies for up to eight targets.

AbCellera Expands Multi-Target Antibody Discovery Collaboration ...

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron. The collaboration, which began in March 2020, leverages AbCellera's antibody ...

AbCellera to Collaborate with Biogen to Discover Therapeutic ...

AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target ...

AbCellera's First Program with Regeneron in Multi-Target ...

Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target ...

The Antibody Society on LinkedIn: AbCellera Expands Multi-Target ...

In business news, AbCellera announced that it has expanded its existing multi-target collaboration with Regeneron to discover therapeutic ...

AbCellera and Lilly broadens antibody discovery partnership

In the expanded deal, Lilly will hold the rights for the development and commercialisation of any therapeutic antibodies that emerge from the ...

AbCellera and Empirico Expand Strategic Multi-Target Antibody ...

(“Empirico”) announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico's Precision ...

EX-99.1 - SEC.gov

Exhibit 99.1. AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration. Expanded collaboration ...

Gilead expands AbCellera antibody discovery pact to access rival to ...

Based on the early-stage nature of the collaboration—and the revenues AbCellera booked in other years in which it struck multi-target deals—the ...

AbCellera and Invetx Expand Multi-Year Antibody Discovery ...

AbCellera and Invetx Expand Multi-Year Antibody Discovery Collaboration in Animal Health · VANCOUVER, British Columbia, and BOSTON, November 19, ...

AbCellera on X: "AbCellera Expands Multi-Target Antibody ...

AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron https://t.co/S2sMh2vzps.

AbCellera and Gilead Sciences Announce New Multi-Year, Multi ...

Expanded collaboration includes an eight-target discovery partnership ... Multi-Year, Multi-Target Antibody Discovery Collaboration. April 01 ...

AbCellera Announces Multi-Target Research Collaboration with Pfizer

Vancouver, Canada (January 5, 2017) - AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with ...

AbCellera Announces Multi-Year Antibody Discovery Collaboration ...

... collaboration. AbCellera and Lilly were in discussions about the multi-target agreement in early 2020 when the COVID-19 pandemic emerged.

AbCellera and Empirico Expand Strategic Multi-Target Antibody ...

(“Empirico”) announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico's Precision ...

AbCellera Biologics Inc. Expands Multi-Target Antibody Discovery ...

AbCellera Biologics Inc. announced that it has expanded its existing multi-target collaboration with Regeneron to discover therapeutic ...

AbCellera and Empirico Announce Strategic Multi-Target Antibody ...

(“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration. Through each company's proprietary ...